吉非替尼治疗晚期非小细胞肺癌的临床疗效及安全性  

Clinical efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer

作　　者：马立辉 韩云娟 MA Lihui;HAN Yunjuan(Department of Pharmacy,Liaocheng Guangming Eye Hospital,Shandong Province,Liaocheng 252000,China)

机构地区：[1]山东省聊城市光明眼科医院药剂科,252000

出　　处：《临床合理用药杂志》2021年第4期11-12,17,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察吉非替尼治疗晚期非小细胞肺癌的临床疗效及安全性。方法选择2016年12月-2018年12月在山东省聊城市光明眼科医院接受治疗的晚期非小细胞肺癌患者84例,按照随机数字表法分为观察组和对照组,每组42例。观察组选择吉非替尼治疗,对照组选择厄洛替尼治疗。比较2组患者临床疗效和不良反应。结果观察组患者治疗总有效率为95.2%,高于对照组的81.0%(χ^(2)=4.086,P=0.043);观察组患者不良反应总发生率为4.8%,低于对照组的19.0%(χ^(2)=4.086,P=0.043)。结论吉非替尼治疗晚期非小细胞肺癌可有效提升整体效果,改善患者病情,不会产生相对严重不良反应,临床应用安全性更高。Objective To observe the clinical efficacy and safety of gefitinib in the treatment of advanced non-small cell lung cancer. Methods A total of 84 patients with advanced non-small cell lung cancer who were treated in Guangming Eye Hospital of Liaocheng City,Shandong Province from December 2016 to December 2018 were selected. According to the random number table method,they were divided into observation group and control group,with 42 cases in each group. The observation group was treated with gefitinib,and the control group was treated with erlotinib. The clinical efficacy and adverse reactions of the two groups were compared. Results The total effective rate of treatment in the observation group was 95. 2%,which was higher than 81. 0% in the control group( χ^(2)= 4. 086,P = 0. 043);the total incidence of adverse reactions in the observation group was 4. 8%,which was lower than 19. 0% in the control group( χ^(2)= 4. 086,P = 0. 043). Conclusion Gefitinib can effectively promote the overall treatment effect,and improve the patient’ s condition,without relatively serious adverse reactions,clinical application of safety is more significant.

关 键 词：吉非替尼 非小细胞肺癌 晚期 临床疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]